Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Detrol Sales Potential Could Be $1 Bil. With Once-Daily Indication, P&U Says

Executive Summary

The sales potential of Pharmacia & Upjohn's overactive bladder treatment Detrol (tolterodine) could be up to half a billion dollars greater than previous projections, pending approval of a once-daily formulation.

You may also be interested in...



Pharmacia Detrol LA Once-Daily Formulation To Be Promoted By 2,000 Reps

Pharmacia will use 2,000 sales reps to promote Detrol LA, the company said following the Dec. 22 approval of the once-daily formulation of its overactive bladder drug tolterodine.

Pharmacia Detrol LA Once-Daily Formulation To Be Promoted By 2,000 Reps

Pharmacia will use 2,000 sales reps to promote Detrol LA, the company said following the Dec. 22 approval of the once-daily formulation of its overactive bladder drug tolterodine.

Vestra

P&U receives second "approvable" letter for the reboxetine antidepressant Feb. 23. P&U said it conducted two U.S. trials for Vestra to supplement the non-U.S. data in its NDA following the first "approvable" letter in July, but only one showed efficacy on the primary endpoint (1"The Pink Sheet" Feb. 14, p. 29)

Related Content

UsernamePublicRestriction

Register

OM004634

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel